{
  "data_version": "seed-0.7 · marketcap-1 · 2026-08-30",
  "source": "https://finance.foundation",
  "license": {
    "finance_foundation_data": "CC BY 4.0 — attribution: Finance Foundation (https://finance.foundation)",
    "upstream_values": "Fields sourced from a provider carry their own source field and remain under that provider's terms — see https://finance.foundation/api/v1/sources"
  },
  "entity": "company",
  "data": {
    "id": "novartis",
    "name": "Novartis",
    "legal_name": "Novartis AG",
    "ticker": "NOVN",
    "exchange": "six",
    "country": "switzerland",
    "sector": "Healthcare",
    "industry": "Pharmaceuticals",
    "market_cap_usd_bn": 292.4,
    "currency": "CHF",
    "website": "https://www.novartis.com",
    "founded": 1996,
    "description": "Basel-based pharmaceutical company created by the 1996 merger of Ciba-Geigy and Sandoz, now a pure-play innovative-medicines business after spinning off Alcon and Sandoz. Key franchises include cardiovascular, oncology and immunology drugs.",
    "identifiers": {
      "lei": "5493007HIVTX6SY6XD66",
      "isin": "CH0012005267",
      "figi": "BBG001SD31N7"
    },
    "market_cap_seed_usd_bn": 230,
    "market_cap_basis": "computed",
    "market_cap_as_of": "2026-08-28",
    "market_cap": {
      "usd_bn": 292.4,
      "method": "shares_outstanding x price",
      "shares_outstanding": 1900714840,
      "shares_basis": "outstanding",
      "shares_as_of": "2026-06-30",
      "shares_source": "Novartis Q2/H1 2026 Condensed Interim Financial Report, filed as SEC Form 6-K Exhibit 99.2, \"Share...",
      "shares_source_url": "https://www.sec.gov/Archives/edgar/data/1114448/000111444826000012/nvs-20260630-99_2.htm",
      "price": 123.74,
      "price_currency": "CHF",
      "price_date": "2026-08-28",
      "price_symbol": "NOVN.SW",
      "price_venue": "Swiss",
      "fx": "ECB euro reference rates, 2026-08-28",
      "adr_ratio": 1,
      "caveat": "This is shares outstanding excluding treasury shares - the basis Novartis itself uses (footnote: \"Market capitalization is calculated based on the number of shares outstanding (excluding treasury shares)\"), and it reconciles with the company's own published market cap. Do NOT use the registered/issued count: 2,112,421,867 registered shares of CHF 0.49 nominal at 31 Dec 2025, of which about 9.6% were held in treasury - using the issued number would overstate market cap by roughly 10%."
    }
  },
  "field_provenance": {
    "market_cap_usd_bn": "Computed, not copied: shares outstanding from the issuer's own filing x the closing price on its home listing. The inputs, their dates and the filing URL are in the `market_cap` object; null means we hold no share count we can source. `market_cap_seed_usd_bn` is the superseded hand-entered value, kept only so the two can be told apart.",
    "founded": "Company's own corporate history / registration record.",
    "sector": "Finance Foundation classification, not GICS or ICB (both licensed).",
    "identifiers": {
      "lei": "GLEIF (CC0) — free to redistribute",
      "isin": "Issuer's own primary listing document; ISO 6166 check digit validated. For a company carried via its US ADR this is the ADR ISIN — see us_listing_type",
      "figi": "OpenFIGI (open standard) — free to redistribute"
    }
  },
  "links": {
    "html": "https://finance.foundation/companies/novartis",
    "graph": "https://finance.foundation/api/v1/graph/companies/novartis",
    "sources": "https://finance.foundation/api/v1/sources"
  }
}